101 related articles for article (PubMed ID: 17883115)
1. Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions.
Marwah N; Bansal C; Gupta S; Singh S; Sapna ; Arora B
Indian J Pathol Microbiol; 2007 Jul; 50(3):489-92. PubMed ID: 17883115
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.
Khalifa MA; Lacher DA; Lage JM; Mannel RS; Walker JL; Angros LH; Min KW
Cancer Detect Prev; 1997; 21(6):532-9. PubMed ID: 9398993
[TBL] [Abstract][Full Text] [Related]
4. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
[TBL] [Abstract][Full Text] [Related]
5. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
7. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
8. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
9. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
10. Neu oncogene expression in ovarian tumors: a quantitative study.
Huettner PC; Carney WP; Naber SP; DeLellis RA; Membrino W; Wolfe HJ
Mod Pathol; 1992 May; 5(3):250-6. PubMed ID: 1353878
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
13. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes.
Skálová A; Sima R; Vanecek T; Muller S; Korabecna M; Nemcova J; Elmberger G; Leivo I; Passador-Santos F; Walter J; Rousarova M; Jedlickova K; Curik R; Geierova M; Michal M
Am J Surg Pathol; 2009 Aug; 33(8):1137-45. PubMed ID: 19461506
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study.
Nowee ME; Dorsman JC; Piek JM; Kosma VM; Hämäläinen K; Verheijen RH; van Diest PJ
Histopathology; 2007 Nov; 51(5):666-73. PubMed ID: 17927588
[TBL] [Abstract][Full Text] [Related]
15. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
18. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.
Hsu CY; Ho DM; Yang CF; Lai CR; Yu IT; Chiang H
Am J Clin Pathol; 2002 Nov; 118(5):693-8. PubMed ID: 12428788
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia.
Menczer J; Schreiber L; Berger E; Golan A; Levy T
Gynecol Oncol; 2007 Mar; 104(3):675-9. PubMed ID: 17126893
[TBL] [Abstract][Full Text] [Related]
20. Is Her-2/neu expressed in nonepithelial ovarian malignancies?
Menczer J; Schreiber L; Czernobilsky B; Berger E; Golan A; Levy T
Am J Obstet Gynecol; 2007 Jan; 196(1):79.e1-4. PubMed ID: 17240244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
